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BACKGROUND: To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in
pre-treated metastatic colorectal cancer (mCRC) patients.
METHODS: Pre-treatment serum levels of 24 cytokines were measured using a multiplex bead assay (MBA) in 32 pre-treated mCRC
patients treated with irinotecan plus bevacizumab-based salvage therapy. Macrophage-derived chemokine (MDC), interleukins (ILs)
8 and 6 levels were also validated by enzyme-linked immunosorbent assay (ELISA) at different time points during therapy.
RESULTS: Higher epidermal growth factor (EGF) and MDC baseline levels (2.2- and 1.4-fold, respectively) and lower IL-10, IL-6 and
IL-8 levels (0.2-, 0.6-, and 0.6-fold, respectively, Po0.05) were observed in patients responding to therapy. Baseline levels of these
five serum factors compose a risk signature that may define the subset of patients most likely to benefit from bevacizumab-based
therapy in terms of response rate and survival times. A positive correlation was found between MBA and ELISA results (Po0.01).
Treatment exposure increased MDC and had opposite effects on IL-8 levels, which were decreased (Po0.05).
CONCLUSION: This study suggests that a set of inflammatory and angiogenesis-related serum markers may be associated with the
efficacy of bevacizumab-containing regimen.
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Anti-VEGF therapies have proven efficacy in metastatic colorectal
cancer (mCRC) (Kabbinavar et al, 2003; Emmanoulide C, 2004;
Hurwitz et al, 2004), although varying degrees of benefit in patients
outcome have been reported (Giantonio et al, 2007; Lievre et al,
2009). Several mechanisms of resistance to the angiogenics blockade,
either by target mutation or by activation of alternative pathways
(Bergers and Hanahan, 2008; Ellis and Hicklin, 2008; Shojaei and
Ferrara, 2008) have been described. Nevertheless, further insight into
the biological mechanisms responsible for the observed differences
in outcome seem warranted (Saito and Camilleri, 2006).
Serum circulating cytokines, growth factors and angiogenesis-
related molecules, are hypothesised to be valid markers of the
tumour microenvironment angiogenic profile and may offer
prognostic and predictive information beyond conventional
clinico-pathological indicators (Poon et al, 2001). Extensive
research suggests the prognostic value of angiogenesis-related
factors for tumour stage (Carmeliet and Jain, 2000; Ferrara, 2004)
and plasma concentrations of some of these molecules are
markedly increased in mCRC patients compared with healthy
individuals (Sakamoto et al, 2012). The incorporation of non-
invasive sampling techniques into clinical routine, avoiding the
need for invasive biopsy procedures is of paramount importance
in a palliative setting and allows a dynamic evaluation of putative
candidate biomarkers (Jain et al, 2009). The intrinsic complexity of
the tumour microenvironment requires a parallel, miniaturised
device technology to be applied to proteins and their biochemical
pathways (Huang et al, 2005). Prior studies have reported
promising results with the use of multiplex bead assay (MBA) as
an alternative to simultaneously detect the expression of multiple
cytokines in minimal amounts of sample (Huang et al, 2005).
On this basis, in the present study we performed a MBA-based
exploratory analysis of 24 serum cytokines from mCRC patients
treated with a bevacizumab-containing regimen.
PATIENTS AND METHODS
Patients
Thirty-two histologically confirmed mCRC patients aged 418
years, ECOG 0–2, progressed after one prior oxaliplatin/fluoropyr-
imidine-based chemotherapy regimen for metastatic disease were
selected from a larger cohort (Abajo et al, 2010) based on the
availability of baseline serum samples. Patients’ characteristics
are shown in Supplementary Table 1. Complete cohort staging
work-up, clinical management, treatment administration and
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long-term outcomes have been reported elsewhere (Abajo et al,
2010). The local institutional review board approved the study and
all patients provided written informed consent.
Serum sample collection and pharmacogenomic analysis
Serum samples were obtained at baseline in all patients and
afterwards along the course of therapy after at least two treatment
cycles (17 available samples). Venous blood was drawn and imme-
diately processed for serum. Samples were stored at  80 1C until
analysis. Angiogenic growth factors and cytokines (Supplementary
Table 2) were measured using MBA (Millipore, Bedford, MA, USA)
and macrophage-derived chemokine (MDC), interleukins (IL-8
and IL-6) by ELISA (R&D Systems, Minneapolis, MN, USA) as per
manufacturers’ directions.
Statistical methods
The relationship between continuous variables was assessed by
non-parametric Spearman’s correlation. Association between angio-
genesis-related cytokines levels and patients clinical outcomes was
assessed using the Mann–Whitney U test. Clinical outcomes refers
to objective response (ORR; CR and PR) and disease control rate
(DCR; CR, PR and SD lasting46 months). As determination of an
optimal cutoff value was beyond the scope of the present work,
patients were divided into two groups according to the median value
of each cytokine. Time to progression (TTP) and overall survival
(OS) distributions are summarised by Kaplan–Meier methods and
compared using log-rank or Breslow’s tests. Patients undergoing
consolidative procedure are censored for TTP and patients receiving
further lines of therapy are censored for OS. Differences between
baseline and on-treatment cytokines’ levels were assessed using
Wilcoxon tests. All P-values are two sided.
RESULTS
Baseline (pre-treatment) serum cytokines and growth
factors levels
The baseline levels of the 24 MBA-analysed angiogenesis-related
molecules are shown in Supplementary Table 1, with some of
them being significantly associated with ORR and DCR. As shown
in Figures 1A and B, higher median epidermal growth factor
(EGF) and MDC levels (282.8 vs 138.9 pgml 1 and 838.6 vs
696.9 pgml 1, respectively, Po0.05) were observed in respond-
ing patients. In addition, lower levels of IL-10 (median 0.0
vs 35.7 pgml 1), IL-6 (median 0.0 vs 37.1 pgml 1), and IL-8
(median 30.3 vs 33.6 pgml 1) were also observed in responding
patients (Figures 1C–E).
A statistically significant correlation was found between these
ILs (Po0.01), with similar biological function and most probably
regulated by same effectors; and a negative significant correlation
was observed between MDC and IL-8 and IL-10, which seem to
have opposite roles (Supplementary Table 3).
We next assessed whether the combination of the differentially
expressed serum factors would further increase the predictive
ability of each individual factor. A risk score was thus calculated
for each patient, by summing-up the number of factors below and
above the median for EGF and MDC, and IL-10, IL-6 and IL-8,
respectively. A DCR of 86% was reported among patients witho3
high-risk factors compared with 22% in those with X3 high-risk
factors (Po0.001). Median TTP (8.1 vs 2.8, Po0.05, Breslow’s test;
Figure 2A) and median OS (23.8 vs 5.1, Po0.01, log-rank test;
Figure 2B) were significantly longer in patients with o3 high-risk
factors.
Technical validation of MBA results by ELISA
To validate the MBA results, the levels of IL-6, IL-8 and MDC were
analysed by ELISA. As previously reported (Elshal and McCoy,
2006), MBA detection levels were 1.5–2-fold higher than those
attained by ELISA. In fact, only 8 out of 32 samples had detectable
levels of IL-8 by ELISA (seven out of those eight patients were
non-responders), confirming the higher sensitivity of the MBA
technique. Nevertheless, we found a statistically significant
positive correlation between MBA and ELISA data for the three
analysed cytokines: IL-8 (rSpearman 0.67, Po0.01), IL-6 (rSpearman
0.67, Po0.01) and MDC (rSpearman 0.53, Po0.01). In agreement
with the MBA results, when IL-6 and/or IL-8 ELISA-based
measurements were considered, DCR was 21.4% and 75%
(Po0.001) for those patients with high and low levels, respectively.
In addition, a statistically significant higher ORR was found for
high ELISA-measured MDC levels compared with the low MDC
group (66.7% vs 26.7%, Po0.05).
Treatment influence on serum markers levels
Monitoring the effect of treatment by analysing dynamic changes
in circulating factors has become of great interest to understand
treatment failure (Jain et al, 2006; Kopetz et al, 2010). In the
subset of patients with available on-treatment samples, we
observed that exposure to bevacizumab-based therapy translated
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Figure 1 MBA measured cytokine levels at baseline according to ORR clinical outcome. EGF (A) and MDC (B) are higher in responders (CRþ PR) to
treatment and IL-10 (C), IL-6 (D) and IL-8 (E) are lower in responders to treatment.
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into decreased IL-8 levels and (Po0.05; Figure 3A) increased in the
chemokine MDC (Po0.05; Figure 3B). No relevant changes were
observed for IL-6.
DISCUSSION
Although the addition of bevacizumab to cytotoxic chemo-
therapy has demonstrated a survival benefit in the first-
and second-line treatment of mCRC, the identification of
predictive biomarkers of antiangiogenic therapy efficacy is of
considerable interest. The detection of differentially expressed
molecular profiles by means of simple, reliable, non-invasive
screening tests (Carmeliet and Jain, 2000; Acevedo et al, 2009)
is appealing. Our findings suggest that in this subset of
patients, a baseline circulating molecular signature correlated
with clinical outcome. High serum levels of EGF and MDC
and low levels of IL-10, IL-6 and IL-8 were associated with a
higher likelihood of response. Interestingly, a risk signature
calculated by combining all of these five serum factors signifi-
cantly correlated with TTP and OS, improving single factor’s
predictive ability.
Tumour-derived factors provide an essential support for the
angiogenesis and the stroma remodelling required for tumour
growth. Tumour-associated macrophages represent the major
population of tumour-infiltrating inflammatory cells. MDC attracts
and activates a variety of cell types and enhance the immune
response. Dendritic cells and IL-2-activated natural killer cells have
demonstrated chemotactic response to MDC (Godiska et al, 1997).
Accordingly, high baseline levels of MDC in our responding
patients support its role in promoting an immune response by
T-helper cells recruitment. In vivo MDC has been shown to
suppress lung and colon cancer growth (Cho et al, 2009).
Moreover, an MDC-increased gene expression in tumour tissue
turned out to be a favourable prognostic factor (Nakajima et al,
2006) and its concentration levels strongly correlates with the
frequency of FOXP3-positive cells (Mizukami et al, 2008). A high
density of intratumour FOXP3-positive T-regulatory cells has been
associated with poor outcomes in a wide variety of solid tumours
(Jang, 2008; Maruyama et al, 2010). However, an opposite effect
has been observed in colorectal cancer, with intratumour
regulatory T cells being associated with improved prognosis
(Pages et al, 2005; Wagsater et al, 2008). Subsequently, whether
MDC has a prognostic or a predictive value for mCRC patients’
outcomes deserves further research.
The better outcome observed in the subset of patients with lower
IL-6 and IL-8 baseline levels is in accordance with the role of these
cytokines in colon cancer progression and angiogenesis (Li et al,
2003; Bunger et al, 2011). IL-8 has been reported to mediate
angiogenesis by stimulating endothelial cell proliferation in
response to hypoxia (Koch et al, 1992; Varney et al, 2002), and
escape to antiangiogenic therapy has been correlated with
increased secretion of IL-8 (Huang et al, 2010). Furthermore, the
predictive role of low baseline IL-8 levels and their bevacizumab-
induced decrease are in agreement with recently reported clinical
data (Kopetz et al, 2010).
Given the biological complexity of tumour angiogenesis and the
non-randomised study design, our results should be viewed with
caution. Although there is a biological rationale to support the
present observations, the present data are exploratory and
retrospective. Prospective validation is required because it is
plausible that other inflammatory mediators may arise (Cavallo
et al, 2011; Hanahan and Weinberg, 2011) as a potential predictive
markers of outcomes to angiogenesis blockade.
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